Overview

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee

Status:
NOT_YET_RECRUITING

Trial end date:
2028-05-01

Target enrollment:

Participant gender:

Summary

The GZPT master protocol will support two independent studies, J2A-MC-GZT1 and J2A-MC-GZT2. Each study will see how well and safely orforglipron works in people with obesity or overweight who have osteoarthritis (OA) of the knee with pain. Participation in the study will last about 74 weeks.

Phase:

PHASE3

Details

Lead Sponsor:

Eli Lilly and Company

Treatments:

orforglipron